

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM477466

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
The Medicines Company		01/05/2018	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Melinta Therapeutics, Inc.		
Street Address:	300 George St.		
Internal Address:	Suite 301		
City:	New Haven		
State/Country:	CONNECTICUT		
Postal Code:	06511		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Serial Number:	87668177		
CORRESPONDENCE DATA			
Fax Number:	2125549623		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	2126132023		
Email:	ipdocket@gibbonslaw.com, pstrino@gibbonslaw.com		
Correspondent Name:	Paolo A. Strino		
Address Line 1:	One Pennsylvania Plaza, 37th Floor		
Address Line 4:	New York, NEW YORK 10119-3701		
ATTORNEY DOCKET NUMBER:	115215-98371		
NAME OF SUBMITTER:	Paolo A. Strino		
SIGNATURE:	/PAS/		
DATE SIGNED:	06/11/2018		
Total Attachments: 23			
source=MedCo Trademark Assignment#page1.tif			
source=MedCo Trademark Assignment#page2.tif			
source=MedCo Trademark Assignment#page3.tif			
source=MedCo Trademark Assignment#page4.tif			

CH \$40.00 87668177

source=MedCo Trademark Assignment#page5.tif
source=MedCo Trademark Assignment#page6.tif
source=MedCo Trademark Assignment#page7.tif
source=MedCo Trademark Assignment#page8.tif
source=MedCo Trademark Assignment#page9.tif
source=MedCo Trademark Assignment#page10.tif
source=MedCo Trademark Assignment#page11.tif
source=MedCo Trademark Assignment#page12.tif
source=MedCo Trademark Assignment#page13.tif
source=MedCo Trademark Assignment#page14.tif
source=MedCo Trademark Assignment#page15.tif
source=MedCo Trademark Assignment#page16.tif
source=MedCo Trademark Assignment#page17.tif
source=MedCo Trademark Assignment#page18.tif
source=MedCo Trademark Assignment#page19.tif
source=MedCo Trademark Assignment#page20.tif
source=MedCo Trademark Assignment#page21.tif
source=MedCo Trademark Assignment#page22.tif
source=MedCo Trademark Assignment#page23.tif

TRADEMARK ASSIGNMENT

THIS TRADEMARK ASSIGNMENT dated as of January 5, 2018 (this “Assignment”) is by and between The Medicines Company, a Delaware corporation (“Seller Parent” or “Assignor”) and Melinta Therapeutics, Inc. (“Assignee”).

W I T N E S S E T H:

WHEREAS, Seller Parent and Assignee have entered into a Purchase and Sale Agreement, dated as of November 28, 2017 (the “Purchase Agreement”);

WHEREAS, pursuant to the Purchase Agreement, Seller Parent, on behalf of itself and its subsidiaries, has agreed, among other things, to grant, sell, transfer, convey, assign and deliver to Assignee, and Assignee has agreed to purchase and accept from Seller Parent and its subsidiaries, the Marks and Licensed Marks, as more fully described in the Purchase Agreement and upon the terms and conditions set forth therein.

NOW, THEREFORE, in consideration of the mutual benefits to be derived from this Agreement and of the representations, warranties, conditions, agreements and promises contained in the Purchase Agreement, this Agreement, and the other Ancillary Agreements, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and upon the terms and subject to the conditions set forth herein, the parties hereto hereby agree as follows:

1. Definitions. Unless otherwise specifically provided herein, capitalized terms used but not defined herein shall have the respective meanings ascribed to them in the Purchase Agreement.

2. Assignment. In accordance with the provisions of the Purchase Agreement, Assignor hereby irrevocably and unconditionally grants, sells, transfers, conveys, assigns and delivers to Assignee all of Assignor’s right, title and interest in and to the Marks and Licensed Marks, free and clear of all Liens, other than Permitted Liens. Assignor does further consent to the recordation of this Assignment by Assignee with the United States Patent and Trademark Office.

3. Further Assurances. Assignee shall be solely responsible for all actions and all costs whatsoever, including attorney’s fees, arising after the date hereof and associated with the registration and the renewal of the Marks and Licensed Marks, and Assignor shall have no obligation to pay any registration costs and/or renewal fees which become due for such Marks or Licensed Marks after the date hereof. Assignee shall be responsible for preparing and translating any documents that Assignee records to perfect its right, title and interest in the Marks and Licensed Marks in any jurisdiction and all costs and fees associated with such recordation documents.

4. No Modification of the Purchase Agreement. Notwithstanding any other provision of this Agreement to the contrary, nothing contained herein shall release Seller Parent or Assignee from any of their respective obligations under the Purchase Agreement or in any way supersede, modify, replace, amend, change, rescind, waive, exceed, expand, enlarge or in any way affect the provisions, including warranties, covenants, agreements, conditions, representations, or in general any of the rights and remedies or any of the obligations of Assignee or Seller Parent set forth in the Purchase Agreement. In the event of any conflict or inconsistency between the terms

of the Purchase Agreement and the terms hereof, the terms of the Purchase Agreement shall govern.

5. General Provisions. Sections 1.2, 6.13, 13.1, 13.4, 13.5, 13.7, 13.8, 13.9, 13.10, 13.13, and 13.14 of the Purchase Agreement are each hereby incorporated by reference herein mutatis mutandis.

[Signature Page Follows]

IN WITNESS WHEREOF, each of Assignor and Assignee have caused this instrument to be signed by its proper and duly authorized officer as of the date and year first written above.

THE MEDICINES COMPANY

By: 

Name: Stephen M. Rodin
Title: Executive Vice President and
General Counsel

IN WITNESS WHEREOF, each of Assignor and Assignee have caused this instrument to be signed by its proper and duly authorized officer as of the date and year first written above.

MELINTA THERAPEUTICS, INC.

By: Paul D. Estrem
Name: Paul Estrem
Title: Chief Financial Officer

PURCHASE AND SALE AGREEMENT

dated as of November 28, 2017

by and between

THE MEDICINES COMPANY

and

MELINTA THERAPEUTICS, INC.

TABLE OF CONTENTS

Page

[REDACTED]

ARTICLE II. PURCHASE AND SALE24

2.1. Agreement to Purchase and Sell24

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Schedule 2.1(b)(iv)(C) – Marks

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

PURCHASE AND SALE AGREEMENT

This Purchase and Sale Agreement (this “**Agreement**”), dated as of November 28, 2017, is entered into by and between Melinta Therapeutics, Inc., a Delaware corporation (“**Buyer**”), and The Medicines Company, a Delaware corporation (“**Seller Parent**”). Seller Parent and the Subsidiaries of Seller Parent that are party to any Transfer Document are referred to in this Agreement each as a “**Seller**” and collectively as “**Sellers**” (which definition, for the avoidance of doubt, excludes the Transferred Group). Seller Parent and Buyer sometimes are referred to in this Agreement collectively as the “**Parties**” and individually as a “**Party**.”

WHEREAS, Sellers and the Transferred Group are engaged in, among other things, the Business; and

WHEREAS, Seller Parent wishes to sell, and to cause the other Sellers to sell, to Buyer, and Buyer wishes to purchase, the Business through the purchase from Sellers of all of the Acquired Assets, consisting of the Transferred Shares and Transferred Assets, [REDACTED]

NOW, THEREFORE, in consideration of the premises and mutual covenants, agreements and provisions herein contained, the Parties agree as follows:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

“**Intellectual Property**” means intellectual property or other proprietary rights anywhere in the world, including registered, unregistered, applied for and pending rights, arising out of or related to:

[REDACTED]

(b) indicia of source, brands, trademarks, service marks, trade names, trade dress, corporate names, logos, internet domain names, social media accounts, URLs, in each case whether or not registered, together with derivations and combinations thereof, and common law rights thereto, and the goodwill associated with the foregoing, and applications (including intent to use applications), registration and renewals of the foregoing (collectively, “**Trademark Rights**”):

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

ARTICLE II.

PURCHASE AND SALE

2.1. Agreement to Purchase and Sell. At the Closing, in accordance with and pursuant to the terms and conditions of this Agreement, for the consideration specified in Section 2.6, Seller Parent and its Subsidiaries shall grant, sell, transfer, convey, assign and deliver to Buyer, and Buyer shall purchase and accept from Seller Parent and its Subsidiaries, all right, title and interest of Seller Parent and its Subsidiaries, as of the Closing, in and to the following (collectively, the "Acquired Assets"):

[REDACTED]

(b) the following assets, properties, rights and interests. [REDACTED] (collectively, the "Transferred Assets"):

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

(C) the Trademark Rights listed on Schedule 2.1(b)(iv)(C) and all other Trademark Rights, applications and registrations, owned by Seller Parent or any of its Subsidiaries primarily related to the Business, together with all common law rights and goodwill associated therewith (the "Marks");

[REDACTED]

[REDACTED]

[REDACTED]

Section 2.1(b)(iv)(C) – Marks

1. See Exhibit A to this Schedule 2.1(b)(iv)(C) attached hereto for Marks.

Trademark Portfolio

Updated: October 2017

Mark	Owner	Jurisdictions	Goods/Services	Application No.	Filing Date	Registration No.	Registration Date
ORBACTIV	The Medicines Company	Australia	Pharmaceutical preparations, namely, anti-infective preparations and substances.	IR1204701	21 Apr 2014 (WIPO)	IR1204701	21 Apr 2014
ORBACTIV	The Medicines Company	Brazil	Pharmaceutical preparations, namely, anti-infective preparations and substances.	907643558	05 May 2014	(pending)	
ORBACTIV	The Medicines Company	Canada	Pharmaceutical preparations, namely, anti-infective preparations and substances.	1673540	22 Apr 2014	(pending)	
ORBACTIV	The Medicines Company	China	Pharmaceutical preparations, namely, anti-infective preparations and substances.	IR1204701	21 Apr 2014 (WIPO)	IR1204701	30 Dec 2014
ORBACTIV	The Medicines Company	Egypt	Pharmaceutical preparations, namely, anti-infective preparations and substances.	IR1204701	21 Apr 2014 (WIPO)	IR1204701	30 Dec 2014
ORBACTIV	The Medicines Company	European Union	Pharmaceutical preparations, namely, anti-infective preparations and substances.	IR1204701	21 Apr 2014 (WIPO)	IR1204701	30 Dec 2014
ORBACTIV	The Medicines Company	India	Pharmaceutical preparations, namely, anti-infective preparations and substances.	2721870	21 Apr 2014	(pending)	
ORBACTIV	The Medicines Company	International Registration (WIPO)	Pharmaceutical preparations, namely, anti-infective preparations and substances.	1204701	21 Apr 2014 (WIPO)	1204701	21 Apr 2014

Mark	Owner	Jurisdictions	Goods/Services	Application No.	Filing Date	Registration No.	Registration Date
ORBACTIV	The Medicines Company	Japan	Pharmaceutical preparations, namely, anti-infective preparations and substances.	IR1204701	21 Apr 2014 (WIPO)	IR1204701	30 Dec 2014
ORBACTIV	The Medicines Company	Kazakhstan	Pharmaceutical preparations, namely, anti-infective preparations and substances.	IR1204701	21 Apr 2014 (WIPO)	IR1204701	21 Apr 2014
ORBACTIV	The Medicines Company	Korea (South)	Pharmaceutical preparations, namely, anti-infective preparations and substances.	IR1204701	21 Apr 2014 (WIPO)	IR1204701	21 Apr 2014
ORBACTIV	The Medicines Company	Mexico	Pharmaceutical preparations, namely, anti-infective preparations and substances.	IR1204701	21 Apr 2014 (WIPO)	IR1204701	30 Dec 2014
ORBACTIV	The Medicines Company	Norway	Pharmaceutical preparations, namely, anti-infective preparations and substances.	IR1204701	21 Apr 2014 (WIPO)	IR1204701	21 Apr 2014
ORBACTIV	The Medicines Company	New Zealand	Pharmaceutical preparations, namely, anti-infective preparations and substances.	IR1204701	21 Apr 2014 (WIPO)	IR1204701	21 Apr 2014
ORBACTIV	The Medicines Company	Russia	Pharmaceutical preparations, namely, anti-infective preparations and substances.	IR1204701	21 Apr 2014 (WIPO)	IR1204701	21 Apr 2014
ORBACTIV	The Medicines Company	Singapore	Pharmaceutical preparations, namely, anti-infective preparations and substances.	IR1204701	21 Apr 2014 (WIPO)	IR1204701	21 Apr 2014
ORBACTIV	The Medicines Company	Switzerland	Pharmaceutical preparations, namely, anti-infective preparations and substances.	IR1204701	21 Apr 2014 (WIPO)	IR1204701	21 Apr 2014
ORBACTIV	The Medicines Company	Turkey	Pharmaceutical preparations, namely, anti-infective preparations and substances.	IR1204701	21 Apr 2014 (WIPO)	IR1204701	21 Apr 2014

USActive 38004548.24

Schedules - 110

Mark	Owner	Jurisdictions	Goods/Services	Application No.	Filing Date	Registration No.	Registration Date
ORBACTIV	The Medicines Company	Ukraine	Pharmaceutical preparations, namely, anti-infective preparations and substances.	IR1204701	21 Apr 2014 (WIPO)	IR1204701	21 Apr 2014
ORBACTIV	The Medicines Company	United States	Pharmaceutical preparations, namely, anti-infective preparations and substances.	86/120,316	15 Nov 2013	4,664,703	30 Dec 2014
ORBACTIV	The Medicines Company	Vietnam	Pharmaceutical preparations, namely, anti-infective preparations and substances.	IR1204701	21 Apr 2014 (WIPO)	IR1204701	21 Apr 2014
ORBACTIV	The Medicines Company	South Africa	Pharmaceutical preparations, namely, anti-infective preparations and substances.	2014/10290	22 Apr 2014	(pending)	
TARGANTA	The Medicines Company	Argentina	All the goods in International Class 05.	2797811	15 Jan 2008	2268123	22 Jan 2009
TARGANTA	The Medicines Company	Australia	Pharmaceutical preparations.	1215485	14 Dec 2007	1215485	14 Dec 2007
TARGANTA	The Medicines Company	Chile	Pharmaceutical preparations.	800857	24 Dec 2007	823466	01 Aug 2008
TARGANTA	The Medicines Company	Hong Kong	Pharmaceutical preparations.	301015631	17 Dec 2007	301015631	17 Dec 2007
TARGANTA	The Medicines Company	Iceland	Pharmaceutical preparations.	4386/2007	17 Dec 2007	251/2008	03 Mar 2008
TARGANTA	The Medicines Company	Japan	Pharmaceutical products for the treatment of infectious diseases and pharmaceutical products for the prevention of infectious diseases.	2007-124166	14 Dec 2007	5150884	11 Jul 2008

Schedules - 111

USActive 38004548.24

Mark	Owner	Jurisdictions	Goods/Services	Application No.	Filing Date	Registration No.	Registration Date
TARGANTA	The Medicines Company	Mexico	Pharmaceutical preparations.	904026	19 Dec 2007	1026536	19 Dec 2007
TARGANTA	The Medicines Company	New Zealand	Pharmaceutical preparations.	781556	30 Oct 2007	781556	30 Oct 2007
TARGANTA	The Medicines Company	Norway	Pharmaceutical preparations.	200715930	19 Dec 2007	244538	28 Feb 2008
TARGANTA	The Medicines Company	Russia	Pharmaceutical preparations.	2007739807	18 Dec 2007	369556	18 Dec 2007
TARGANTA	The Medicines Company	Singapore	Pharmaceutical preparations.	T0724102D	27 Dec 2007	T0724102D	27 Dec 2007
TARGANTA	The Medicines Company	Switzerland	Pharmaceutical preparations.	64354/2007	18 Dec 2007	571357	18 Dec 2007
TARGANTA	The Medicines Company	Taiwan	Pharmaceutical preparations for the treatment of infections.	096060963	28 Dec 2007	01334632	01 Nov 2008
VAYMERIS	The Medicines Company	United States	IC 005. Pharmaceutical preparations, namely, antifungal preparations IC 044. Medical services; conducting medical physical evaluations; consulting services in the field of medical care; medical advisory services; medical assistance; medical consultations; medical counseling; medical information	87/048,237	24 May 2016	(pending)	

Schedules - 112

USActive 38004548.24

Mark	Owner	Jurisdictions	Goods/Services	Application No.	Filing Date	Registration No.	Registration Date
VABOMERE	The Medicines Company	Australia	Pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations	A0070136	25 Sep 2017	(pending)	
VABOMERE	The Medicines Company	Brazil	Pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations	913463426	27 Sep 2017	(pending)	
VABOMERE	The Medicines Company	Canada	Pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations	TBA	TBA	(pending)	
VABOMERE	The Medicines Company	China	Pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations	A0070136	25 Sep 2017	(pending)	

Schedules - 113

USActive 38004548.24

Mark	Owner	Jurisdictions	Goods/Services	Application No.	Filing Date	Registration No.	Registration Date
VABOMERE	The Medicines Company	Colombia	Pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations	A0070136	25 Sep 2017	(pending)	
VABOMERE	The Medicines Company	European Union	Pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations	A0070136	25 Sep 2017	(pending)	
VABOMERE	The Medicines Company	Israel	Pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations	A0070136	25 Sep 2017	(pending)	
VABOMERE	The Medicines Company	India	Pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations	A0070136	25 Sep 2017	(pending)	

USActive 38004548.24

Schedules - 114

Mark	Owner	Jurisdictions	Goods/Services	Application No.	Filing Date	Registration No.	Registration Date
VABOMERE	The Medicines Company	International Registration (WIPO)	Pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations	A0070136	25 Sep 2017	(pending)	
VABOMERE	The Medicines Company	Japan	Pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations	A0070136	25 Sep 2017	(pending)	
VABOMERE	The Medicines Company	Korea (South)	Pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations	A0070136	25 Sep 2017	(pending)	
VABOMERE	The Medicines Company	Laos	Pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations	40025	28 Sep 2017	(pending)	

USActive 38004548,24

Schedules - 115

Mark	Owner	Jurisdictions	Goods/Services	Application No.	Filing Date	Registration No.	Registration Date
VABOMERE	The Medicines Company	Malaysia	Pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations	2017068939	29 Sep 2017	(pending)	
VABOMERE	The Medicines Company	Mexico	Pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations	A0070136	25 Sep 2017	(pending)	
VABOMERE	The Medicines Company	New Zealand	Pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations	A0070136	25 Sep 2017	(pending)	
VABOMERE	The Medicines Company	Singapore	Pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations	A0070136	25 Sep 2017	(pending)	

Mark	Owner	Jurisdictions	Goods/Services	Application No.	Filing Date	Registration No.	Registration Date
VABOMERE	The Medicines Company	South Africa	Pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations	2017/28149	27 Sep 2017	(pending)	
VABOMERE	The Medicines Company	Switzerland	Pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations	62034/2017	27 Sep 2017	(pending)	
VABOMERE	The Medicines Company	Thailand	Pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations	170134532	28 Sep 2017	(pending)	
VABOMERE	The Medicines Company	United States	Pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations	87/394,992	31 May 2017	(pending)	

Schedules - 117

USActive 38004548.24

Mark	Owner	Jurisdictions	Goods/Services	Application No.	Filing Date	Registration No.	Registration Date
VABOMERE (logo 1)	The Medicines Company	United States	Pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations	87/668,177	1 Nov 2017	(pending)	
VABOMERE (logo 2)	The Medicines Company	United States	Pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations	87/668,224	1 Nov 2017	(pending)	
MERVABIA	The Medicines Company	United States	Pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations	87/398,223	04 Apr 2017	(pending)	
BAVREM	The Medicines Company	United States	Pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations	87/398,187	04 Apr 2017	(pending)	

Mark	Owner	Jurisdictions	Goods/Services	Application No.	Filing Date	Registration No.	Registration Date
CARBAVANCE	Rempex Pharmaceuticals, Inc.	Canada	Pharmaceuticals, namely pharmaceutical preparations for the treatment of infections, namely, gram-negative infections, blood stream infections, urinary tract infections, intra-abdominal infections, bacterial pneumonians, and febrile neutropenia; antibiotics.	1598165	11 Oct 2012	(pending)	
CARBAVANCE	Rempex Pharmaceuticals, Inc.	Europe	Class 5: Pharmaceuticals; antibiotics	11256534	11 Oct 2012	11256534	20 Feb 2013
CARBAVANCE	Rempex Pharmaceuticals, Inc.	United States	Pharmaceuticals, namely, pharmaceutical preparations for the treatment of infections; Antibiotics, in class 5	85/595,007	11 Apr 2012	4777486	21 July 2015

USActive 38004548.24

Schedules - 119

TRADEMARK

REEL: 006350 FRAME: 0687

RECORDED: 06/11/2018